keyword
MENU ▼
Read by QxMD icon Read
search

Dotation

keyword
https://www.readbyqxmd.com/read/28920501/kidney-dosimetry-during-177-lu-dotatate-therapy-in-patients-with-neuroendocrine-tumors-aspects-on-calculation-and-tolerance
#1
Mattias Sandström, Ulrike Garske-Román, Silvia Johansson, Dan Granberg, Anders Sundin, Nanette Freedman
BACKGROUND: Fractionated therapy with (177)Lu-DOTATATE has been reported to be an effective treatment for patients with metastasized neuroendocrine tumors. To optimize the treatment, absorbed doses to risk organs are calculated for the individual patient. For each organ, absorbed dose due to activity in the organ itself (self-dose) and that originating from other organs (cross-dose) are calculated from serial measurements to obtain the activity distribution following treatment. The main aim of the present work were to calculate the cross-dose contribution to the total absorbed kidney dose...
September 18, 2017: Acta Oncologica
https://www.readbyqxmd.com/read/28890865/functional-imaging-of-paragangliomas-with-an-emphasis-on-von-hippel-lindau-associated-disease-a-mini-review
#2
REVIEW
Ioannis Ilias, Georgios Meristoudis
Few reports have presented data and results on functional (i.e., nuclear medicine) imaging of paragangliomas and pheochromocytomas (PGLs/PHEOs) for von Hippel-Lindau (VHL) patients. Nuclear medicine localization modalities for chromaffin tumors can be specific or nonspecific. Specific methods make use of the expression of the human norepinephrine transporter (hNET) and vesicular monoamine transporters (VMATs) by these tumors. These permit the use of radiolabeled ligands that enter the synthesis and storage pathway of catecholamines...
2017: Journal of Kidney Cancer and VHL
https://www.readbyqxmd.com/read/28872545/concomitant-177lu-dotatate-and-capecitabine-therapy-in-patients-with-advanced-neuroendocrine-tumors-a-long-term-outcome-toxicity-survival-and-quality-of-life-study
#3
Sanjana Ballal, Madhav P Yadav, Nishikant A Damle, Ranjit K Sahoo, Chandrasekhar Bal
PURPOSE: The purpose of this study was to evaluate the outcome, toxicity, survival, and quality of life in patients with advanced neuroendocrine tumors. METHODS: One hundred sixty-seven patients were enrolled in the study. All patients underwent baseline Ga-DOTANOC PET/CT scans. Lu-DOTATATE therapy was administered quarterly along with oral capecitabine therapy in group 1 patients (n = 88), whereas group 2 patients (n = 79) were treated only with Lu-DOTATATE. Hematologic, kidney function, liver function tests and chromogranin A levels were recorded before and after therapy at 2-week, 4-week, and 3-month intervals...
September 1, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28864614/somatostatin-receptor-antagonists-for-imaging-and-therapy
#4
Melpomeni Fani, Guillaume P Nicolas, Damian Wild
Somatostatin receptor (sstr) scintigraphy for imaging and sstr analogs for treatment have been used for more than 20 y. An important improvement in recent years was the introduction of peptide receptor radionuclide therapy with radiolabeled sstr agonists, such as [(90)Y-DOTA(0),Tyr(3)]octreotide or [(177)Lu-DOTA(0),Tyr(3)]octreotide ((90)Y- or (177)Lu-DOTATOC, respectively) and [(177)Lu-DOTA(0),Tyr(3)]octreotate ((177)Lu-DOTATATE). PET/CT with (68)Ga-labeled sstr agonists, such as (68)Ga-DOTATOC, (68)Ga-DOTATATE, and [(68)Ga-DOTA,1-Nal(3)]octreotide ((68)Ga-DOTANOC), plays an important role in staging and restaging neuroendocrine tumors...
September 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28840066/pituitary-carcinoma-a-case-report-and-discussion-of-potential-value-of-combined-use-of-ga-68-dotatate-and-f-18-fdg-pet-ct-scan-to-better-choose-therapy
#5
Heraldo Mendes Garmes, José Barreto Campello Carvalheira, Fabiano Reis, Luciano de Souza Queiroz, Mateus Dal Fabbro, Vanessa de Fatima Porto Souza, Allan de Oliviera Santos
BACKGROUND: Pituitary carcinoma is extremely rare and carries a very poor prognosis. In most cases, apparently indolent tumors become malignant; however, there are no satisfactory biomarkers for predicting tumor behavior. Thus, scientific advances in the search for new biological markers, diagnostic methods, and therapies are needed to improve the prognosis of these patients. CASE DESCRIPTION: We report the case of a woman with initial diagnosis of nonfunctioning pituitary adenoma which evolved to carcinoma after 4 years...
2017: Surgical Neurology International
https://www.readbyqxmd.com/read/28832377/safety-and-effectiveness-of-177lu-dotatate-peptide-receptor-radionuclide-therapy-after-regional-hepatic-embolization-in-patients-with-somatostatin-expressing-neuroendocrine-tumors
#6
Mohammadali Hamiditabar, Muzammil Ali, Luke Bolek, Gelareh Vahdati, Izabela Tworowska, Ebrahim S Delpassand
PURPOSE: Peptide receptor radionuclide therapy (PRRT) with Lu-DOTATATE is shown to be an effective therapeutic option for somatostatin-expressing neuroendocrine neoplasms. Some concerns are raised over safety of this modality in patients with a history of regional chemoembolization and radionuclide hepatic embolization (CRHE) and is cause of reluctance among some physicians for suggesting Lu-DOTATATE in this patient population. METHODS: We retrospectively reviewed 143 patients with somatostatin-expressing neuroendocrine tumors who underwent Lu-DOTATATE PRRT...
August 21, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28818983/current-concepts-in-68-ga-dotatate-nen-imaging-interpretation-biodistribution-dosimetry-and-molecular-strategies
#7
Lisa Bodei, Valentina Ambrosini, Ken Herrmann, Irvin Modlin
(68)Ga-DOTATATE PET/CT provides information of the location(s) of somatostatin receptor expressing tumors. Integrating this imaging data effectively in patient care requires the clinical history, the histopathology and biomarker information as well as grade, stage and prior imaging. Previous therapies and technical aspects of the study should be considered, given their ability to alter the interpretation of the images. This includes physiologic biodistribution of the radiotracer, as well as conditions that engender false positive results...
August 17, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28806249/epidural-metastases-from-follicular-thyroid-cancer-mimicking-meningiomas-in-68ga-dotatate-pet
#8
Marcus Unterrainer, Harun Ilhan, Andrei Todica, Peter Bartenstein, Nathalie Lisa Albert
We report a woman with multifocal lesions suggestive of meningiomas in MRI, which also presented with high Ga-DOTATATE uptake in PET, a finding characteristic for meningioma. A whole-body staging due to a pathological fracture revealed multiple neoplastic lesions throughout the body without detection of a primary site. Subsequent pathological workup of a lung lesion revealed multifocal metastases from follicular thyroid cancer despite thyroidectomy 10 years ago (without pathological finding), and posttreatment scans after radioiodine therapy confirmed the multiple brain lesions to be metastases as well...
October 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28798227/-68-ga-dotatate-pet-ct-can-be-an-alternative-imaging-method-in-insulinoma-patients
#9
Sadiye Altun Tuzcu, Zafer Pekkolay, Faruk Kılınç, Alpaslan Kemal Tuzcu
Insulinomas are the most common cause of hypoglycemia, resulting from endogenous hyperinsulinism. The diagnosis of insulinoma is established by demonstrating inappropriately high serum insulin concentrations during a spontaneous or induced episode of hypoglycemia. Most insulinomas are islet-cell tumors. They are often small (<2 cm), benign, and difficult to localize with current imaging techniques. Insulinomas can be detected using either noninvasive procedures (e.g., transabdominal ultrasonography, spiral CT, MRI, (111)In-pentetreotide imaging, and (18)F-l-dihydroxyphenylalanine PET) or invasive procedures (e...
September 2017: Journal of Nuclear Medicine Technology
https://www.readbyqxmd.com/read/28798226/image-guided-combination-of-177-lu-dotatate-and-capecitabine-peptide-receptor-chemoradionuclide-therapy-in-metastatic-mediastinal-paraganglioma
#10
Abhiram G Ashwathanarayana, Chinmoy K Biswal, Ashwani Sood, Ashwin S Parihar, Rakesh Kapoor, Bhagwant R Mittal
The peptide receptor radionuclide therapy (PRRT) targets highly expressed somatostatin receptors (SSTR) shown on SSTR imaging in well-differentiated neuroendocrine tumours (NETs) with stable or partial response in majority of inoperable/metastatic NETs patients. However NETs showing increased FDG uptake carry the poor outcome with limited treatment options and role of PRRT is still unclear. Here is a case of young male patient of mediastinal paraganglioma and extensive metastatic disease showing avidity both on SSTR and FDG imaging...
August 10, 2017: Journal of Nuclear Medicine Technology
https://www.readbyqxmd.com/read/28782747/laparoscopic-surgery-for-solitary-insulinoma-in-the-absence-of-ious
#11
Abhay Narendra Dalvi, Mahadeo Namdeo Garale, Yogesh Prabhakar Takalkar, Sameer Ashok Rege, Pinky Manoharlal Thapar, Lila Anurag, Nalini Samir Shah
BACKGROUND: Insulinomas are the most common pancreatic neuroendocrine neoplasms. In spite of adequate pre-operative localisation, conventional surgical methods rely on intraoperative palpation. Intraoperative ultrasonography (IOUS) is said to aid in accurate localisation, decreases morbidity. Laparoscopic removal of pancreatic endocrine neoplasms is beneficial due to magnification and minimal invasion; however, in the absence of IOUS, error of judgement may lead to conversion to open surgery, thereby relying on 'palpation method' to localise the tumour...
August 1, 2017: Journal of Minimal Access Surgery
https://www.readbyqxmd.com/read/28776139/catching-the-zebra-clinical-pearls-and-pitfalls-for-the-successful-diagnosis-of-zollinger-ellison-syndrome
#12
REVIEW
Aaron H Mendelson, Mark Donowitz
Zollinger-Ellison syndrome (ZES) results from an ectopic gastrin-secreting tumor leading to peptic ulcer disease, reflux, and chronic diarrhea. While early recognition portends an excellent prognosis with >80% survival at 15 years, symptoms are often nonspecific making the diagnosis difficult to establish. Diagnosis involves a series of tests, including fasting gastrin, gastric pH, chromogranin A, and secretin stimulation. Performing these tests in the correct sequence and at the proper time is essential to avoid inaccurate results...
August 3, 2017: Digestive Diseases and Sciences
https://www.readbyqxmd.com/read/28775205/therapy-related-hematological-malignancies-after-peptide-receptor-radionuclide-therapy-with-177-lu-dota-octreotate-incidence-course-predicting-factors-in-patients-with-gep-nets
#13
Hendrik Bergsma, Kirsten van Lom, Mark Konijnenberg, Boen Kam, Jaap Teunissen, Wouter de Herder, Eric Krenning, Dik Kwekkeboom
Peptide Receptor Radionuclide Therapy (PRRT) may induce long-term toxicity to the bone marrow (BM). The aim of this study was to analyze persistent dysfunction of the hematopoietic system after PRRT with (177)Lu-DOTATATE in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Methods: The incidence and course of persistent hematological dysfunction (PHD) was analyzed in 274 (=GEP-NET) out of 367 patients with somatostatin receptor-positive tumors. PHD was defined as diagnosis of Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Myeloproliferative Neoplasms (MPN), Myelodysplastic/Myeloproliferative neoplasms (MDS/MPN) or otherwise unexplained cytopenia (for more than 6 months)...
August 3, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28775202/pet-mr-imaging-in-the-diagnosis-of-hormone-producing-pituitary-micro-adenoma-a-prospective-pilot-study
#14
Hao Wang, Bo Hou, Lin Lu, Ming Feng, Jie Zang, Shaobo Yao, Feng Feng, Renzhi Wang, Fang Li, Zhaohui Zhu
Purpose: This study was designed to evaluate positron emission tomography/magnetic resonance (PET/MR), using (18)F-FDG and (68)Ga-DOTATATE as tracers, in the detection of hormone-producing pituitary micro-adenoma, where diagnosis is difficult using magnetic resonance imaging (MRI) alone. Methods: A total of 37 patients with elevated hormone levels were recruited, including 19 patients with undiagnosable primary pituitary tumors and 18 patients with suspected recurrent pituitary adenomas (PAs). Patients underwent (18)F-FDG PET/MR and (68)Ga-DOTATATE PET/MR within one week...
August 3, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28759524/adrenocorticotropic-hormone-secreting-neuroendocrine-tumor-of-the-rectum-demonstrated-on-68ga-dotatate-and-18f-fdg-pet-imaging
#15
Jeremy Szajer, Grace Yung, Roberto Russo, Robert Mansberg
An 81-year-old man with Cushing syndrome was referred for a Ga-DOTATATE PET/CT study to investigate for an ectopic source of adrenocorticotropic hormone. The scan demonstrated mildly increased octreopeptide uptake at a rectal mass and focal uptake at multiple regions throughout the bone marrow of the axial skeleton, consistent with metastases. A subsequent F-FDG PET/CT study was performed for further evaluation and demonstrated markedly increased metabolism at the previously identified rectal mass, in addition to the liver and multiple regions throughout the skeleton...
October 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28739143/prediction-of-time-integrated-activity-coefficients-in-prrt-using-simulated-dynamic-pet-and-a-pharmacokinetic-model
#16
Deni Hardiansyah, Ali Asgar Attarwala, Peter Kletting, Felix M Mottaghy, Gerhard Glatting
PURPOSE: To investigate the accuracy of predicted time-integrated activity coefficients (TIACs) in peptide-receptor radionuclide therapy (PRRT) using simulated dynamic PET data and a physiologically based pharmacokinetic (PBPK) model. METHODS: PBPK parameters were estimated using biokinetic data of 15 patients after injection of (152±15)MBq of (111)In-DTPAOC (total peptide amount (5.78±0.25)nmol). True mathematical phantoms of patients (MPPs) were the PBPK model with the estimated parameters...
July 21, 2017: Physica Medica: PM
https://www.readbyqxmd.com/read/28736285/optimization-of-gate-simulations-for-whole-body-planar-scintigraphic-acquisitions-using-the-xcat-male-phantom-with-177-lu-dotatate-biokinetics-in-a-siemens-symbia-t2
#17
G C A Costa, D A B Bonifácio, D Sarrut, T Cajgfinger, M Bardiès
Simulations of planar whole body acquisitions in therapeutic procedures are often extensively time-consuming and therefore rarely used. However, optimising tools and variance reduction techniques can be employed to overcome this problem. In this paper, a variety of features available in GATE are explored and their capabilities to reduce simulation time are evaluated. For this purpose, the male XCAT phantom was used as a virtual patient with (177)Lu-DOTATATE pharmacokinetic for whole body planar acquisition simulations in a Siemens Symbia T2 model...
July 20, 2017: Physica Medica: PM
https://www.readbyqxmd.com/read/28732021/in-vitro-comparison-of-213bi-and-177lu-radiation-for-peptide-receptor-radionuclide-therapy
#18
Ho Sze Chan, Erik de Blois, Alfred Morgenstern, Frank Bruchertseifer, Marion de Jong, Wouter Breeman, Mark Konijnenberg
BACKGROUND: Absorbed doses for α-emitters are different from those for β-emitters, as the high linear energy transfer (LET) nature of α-particles results in a very dense energy deposition over a relatively short path length near the point of emission. This highly localized and therefore high energy deposition can lead to enhanced cell-killing effects at absorbed doses that are non-lethal in low-LET type of exposure. Affinities of DOTA-DPhe1-Tyr3-octreotate (DOTATATE), 115In-DOTATATE, 175Lu-DOTATATE and 209Bi-DOTATATE were determined in the K562-SST2 cell line...
2017: PloS One
https://www.readbyqxmd.com/read/28731009/interlesional-flip-flop-between-68-ga-dotatate-and-fdg-pet-ct-in-thyroglobulin-elevated-negative-iodine-scintigraphy-tenis-syndrome
#19
Sandip Basu, Ashwini Kalshetty, Preeti Fargose
No abstract text is available yet for this article.
January 2017: National Medical Journal of India
https://www.readbyqxmd.com/read/28729431/sandostatin-lar-therapy-differentially-alters-68-ga-dotatate-uptake-in-normal-tissues-compared-to-primary-tumors-and-metastatic-lesions
#20
Narjess Ayati, Sze Ting Lee, Seyed Rasoul Zakavi, Kunthi Pathmaraj, Loai Qatawneh, Aurora Poon, Andrew Scott
Synthetic somatostatin analogs have been posed as a potential source of error in somatostatin receptor imaging by interfering with tumor detection; however, experimental models and clinical studies have shown a complex mechanism of octreotide effect on tumors. This study aimed to assess whether (68)Ga-DOTATATE uptake differs before and after treatment with long-acting somatostatin analogs. Methods: Thirty patients with intermediate to well differentiated neuroendocrine tumors (NET) who underwent (68)Ga-DOTATATE Positron Emission Tomography/Computed Tomography (PET/CT) scanning before and after receiving long-acting repeatable (LAR) Sandostatin were included in the study...
July 20, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
keyword
keyword
96892
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"